This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Estimation and validation of a multiattribute model of Alzheimer disease progression


Stallard, Eric, Kinosian, Bruce, Zbrozek, Arthur S., Yashin, Anatoliy I., Glick, Henry A., Stern, Yaakov


Medical Decision Making, Volume: 30, No.: 6, Pages.: 625-638

Year of Publication



Objectives: To estimate and validate a multiattribute model of the clinical course of Alzheimer disease (AD) from mild AD to death in a high-quality prospective cohort study, and to estimate the impact of hypothetical modifications to AD progression rates on costs associated with Medicare and Medicaid services. Data and Methods: The authors estimated sex-specific longitudinal Grade of Membership (GoM) models for AD patients (103 men, 149 women) in the initial cohort of the Predictors Study (1989–2001) based on 80 individual measures obtained every 6 mo for 10 y. These models were replicated for AD patients (106 men, 148 women) in the 2nd Predictors Study cohort (1997–2007). Model validation required that the disease-specific transition parameters be identical for both Predictors Study cohorts. Medicare costs were estimated from the National Long Term Care Survey. Results: Sex-specific models were validated using the 2nd Predictors Study cohort with the GoM transition parameters constrained to the values estimated for the 1st Predictors Study cohort; 57 to 61 of the 80 individual measures contributed significantly to the GoM models. Simulated, cost-free interventions in the rate of progression of AD indicated that large potential cost offsets could occur for patients at the earliest stages of AD. Conclusions: AD progression is characterized by a small number of parameters governing changes in large numbers of correlated indicators of AD severity. The analysis confirmed that the progression of AD represents a complex multidimensional physiological process that is similar across different study cohorts. The estimates suggested that there could be large cost offsets to Medicare and Medicaid from the slowing of AD progression among patients with mild AD. The methodology appears generally applicable in AD modeling. (PsycINFO Database Record (c) 2012 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Stallard_2010, doi = {10.1177/0272989x10363479}, url = {}, year = 2010, month = {nov}, publisher = {{SAGE} Publications}, volume = {30}, number = {6}, pages = {625--638}, author = {E. Stallard and B. Kinosian and A. S. Zbrozek and A. I. Yashin and H. A. Glick and Y. Stern}, title = {Estimation and Validation of a Multiattribute Model of Alzheimer Disease Progression}, journal = {Medical Decision Making} }


alzheimer’s disease, death and dying, disease course, health care costs, hypothetical, interventions, medicaid, medicaid services, medicare, multiattribute models

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cost and service use study

Type of Outcomes

Service use or cost reductions (incl. hospital use reduction, care home admission delay)

Type of Interventions